Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Inclusion Criteria:

Male or female, 55 years of age or older
Former smokers and current enrolled in LDCT lung cancer screening or those who are detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a 6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and current smokers enrolled in LDCT lung cancer screening, or regular CT and have Lung-RADS 2 category lesions with part-solid or non-solid lung nodule ≥4mm mean diameter detected during screening LDCT or regular CT scans
History of cigarette smoking with ≥ 20 pack years
All current smokers should accept to receive smoking cessation
Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1
Able to swallow study pills
Able to undergo CT
Not allergic to components of study agents
Willing to discontinue current vitamin/mineral supplement use containing components of study agents. A standard multivitamin supplement provided for the study
Willing to comply with proposed visit and treatment schedule
Able to understand and willing to sign a written informed consent document
Participants must have normal organ and marrow function
Willing to use contraception during the intervention period of 6 months (males and females)
Not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period..

Exclusion Criteria:

Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years
Inability to undergo CT
Newly diagnosed nodule meeting Lung-RADS 4 criteria
Have taken doxycycline or tetracycline less than or equal to 2 weeks
Females- pregnant or lactating (throughout the duration of intervention of 6 months)
Unwilling to use effective form of birth control (Males and females) (throughout the duration of intervention of 6 months).